VXRT: Vaxart, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
4 institutions reported holding $24K of Vaxart, Inc. on Form 13F (5 the quarter before). 1 opened a new position and 2 sold out. Shares held by institutions: +104%.
| Largest holders | Shares | Value |
|---|---|---|
| Heritage Wealth Advisors | 29,655 | $18K |
| KINGSWOOD WEALTH ADVISORS, LLC | 10,005 | $6K |
| Archer Investment Corp | 30 | $18 |
| LVM CAPITAL MANAGEMENT LTD/MI | 25,000 | $15 |
Clinical trial readouts
1 Phase 2 or 3 trials by Vaxart, Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-05 (est.) | VXA-CoV2-3.1 | SARS-CoV2 | Phase 2 | 5,485 | Enrollment complete | NCT06672055 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.